B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia

Thrombosis and Haemostasis

Volumn 112, Issue 3, 2014, Pages 537-550

  Liu, Chuan Chuan ^a,b   Wang, Shu Ching ^d   Kao, Chen Wei ^a   Hsieh, Ruey Kuen ^a   Chang, Ming Chih ^a,c   Chang, Yi Fang ^a   Lim, Ken Hong ^a   Chen, Caleb Gonshen ^a,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b YUANPEI UNIVERSITY   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

B cell activating factor; Essential thrombocythaemia; IL 1beta; IL 6; TLR4

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; B CELL ACTIVATING FACTOR; BLOCKING ANTIBODY; INTERLEUKIN 1; JANUS KINASE 2;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEGAKARYOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; UPREGULATION; ADOLESCENT; CELL CULTURE; COCULTURE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; THROMBOCYTE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BLOCKING; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BLOOD PLATELETS; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; JANUS KINASE 2; MALE; MEGAKARYOCYTES; MIDDLE AGED; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPOIESIS; TOLL-LIKE RECEPTOR 4; UP-REGULATION; YOUNG ADULT;

EID: 84933041747     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-11-0949     Document Type: Article

References (61)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
2. Quintas-Cardama A, Kantarjian H, Cortes J, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011; 10: 127–140.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
5. Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962–18967.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
7. Li S, Kralovics R, De Libero G, et al. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations. Blood 2008; 111: 3863–3866.
8. Beer PA, Jones AV, Bench AJ, et al. Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Br J Haematol 2009; 144: 904–908.
9. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev 2011; 25: 229–237.
10. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.
11. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.
12. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
13. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005; 130: 709–715.
14. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219–3225.
15. Siitonen T, Savolainen ER, Koistinen P. Flt-3 ligand does not induce the growth of peripheral blood granulocyte-macrophage colony-forming cells in myeloproliferative disorders. Eur J Haematol 1999; 62: 103–108.
16. Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997; 25: 1–7.
17. Araneda M, Krishnan V, Hall K, et al. Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins. South Med J 2001; 94: 417–420.
18. Zheng C, Yang R, Han Z, et al. TPO-independent megakaryocytopoiesis. Crit Rev Oncol Hematol 2008; 65: 212–222.
19. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997; 18: 343–350.
20. Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010; 237: 205–225.
21. Ng LG, Ng CH, Woehl B, et al. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur J Immunol 2006; 36: 1837–1846.
22. Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9–19.
23. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215–218.
24. Sims GP, Ettinger R, Shirota Y, et al. Identification and characterisation of circulating human transitional B cells. Blood 2005; 105: 4390–4398.
25. Palanichamy A, Barnard J, Zheng B, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 2009; 182: 5982–5993.
26. Landolt-Marticorena C, Wither R, Reich H, et al. Increased expression of B cell activation factor supports the abnormal expansion of transitional B cells in systemic lupus erythematosus. J Rheumatol 2011; 38: 642–651.
27. Daridon C, Pers JO, Devauchelle V, et al. Identification of transitional type II B cells in the salivary glands of patients with Sjogren’s syndrome. Arthritis Rheum 2006; 54: 2280–2288.
28. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260–263.
29. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297–302.
30. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364–1369.
31. Scapini P, Carletto A, Nardelli B, et al. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005; 105: 830–837.
32. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301: 1374–1377.
33. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822–828.
34. Kristinsson SY, Landgren O, Samuelsson J, et al. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010; 95: 1216–1220.
35. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115–126.
36. Maugeri N, Baldini M, Ramirez GA, et al. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res 2012; 129: 267–273.
37. Michiels JJ, Berneman Z, Van Bockstaele D, et al. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174–207.
38. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897–2903.
39. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286–297.
40. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328–2337.
41. Kjaer L, Westman M, Hasselbalch Riley C, et al. A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden. PloS one 2012; 7: e33100.
42. Kremer M, Horn T, Koch I, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol 2008; 32: 928-935.
43. Hagihara M, Higuchi A, Tamura N, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297–5303.
44. Treml LS, Carlesso G, Hoek KL, et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007; 178: 7531–7539.
45. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959–1971.
46. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 2010; 87: 989–999.
47. Sohn SJ, Rajpal A, Winoto A. Apoptosis during lymphoid development. Curr Opin Immunol 2003; 15: 209–216.
48. Bekeredjian-Ding I, Jego G. Toll-like receptors--sentries in the B-cell response. Immunology 2009; 128: 311–323.
49. Jagannathan M, McDonnell M, Liang Y, et al. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia 2010; 53: 1461–1471.
50. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006; 80: 866–874.
51. McDonnell M, Liang Y, Noronha A, et al. Systemic Toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 298–307.
52. Yan ZQ. Regulation of TLR4 expression is a tale about tail. Arterioscler Thromb Vasc Biol 2006; 26: 2582–2584.
53. Kim HA, Seo GY, Kim PH. Macrophage-derived BAFF induces AID expression through the p38MAPK/CREB and JNK/AP-1 pathways. J Leukoc Biol 2011; 89: 393–398.
54. Hasselbalch HC. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 2014; 38: 263–266.
55. Kovacs CJ, Powell DS, Evans MJ, et al. Enhanced platelet recovery in myelosuppressed mice treated with interleukin-1 and macrophage colony-stimulating factor: potential interactions with cytokines having megakaryocyte colonystimulating activity. J Interferon Cytokine Res 1996; 16: 187–194.
56. Chuen CK, Li K, Yang M, et al. Interleukin-1beta up-regulates the expression of thrombopoietin and transcription factors c-Jun, c-Fos, GATA-1, and NF-E2 in megakaryocytic cells. J Lab Clin Med 2004; 143: 75–88.
57. Kaufmann KB, Grunder A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med 2012; 209: 35–50.
58. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720–2725.
59. Alexandrakis MG, Passam FH, Moschandrea IA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140.
60. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47: 1013–1017.
61. Giezen TJ, Mantel-Teeuwisse AK, ten Berg MJ, et al. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol 2012; 89: 256–266.